Medicines Used for Coronary Heart Disease and the Relevance of their Improvement

Coronary artery disease (CAD) is one of the most common causes of death worldwide. In the previous decade, major breakthroughs in CAD therapy have been made. The existing treatment is medicinal, surgical or a combination of both depending on the amount, severity and clinical presentation of CAD. The partnership of multiple research disciplines such as biotechnology and tissue engineering has led to the creation of novel therapeutic tactics such as stem cells, nanotechnology, robotic surgery and other improvements (3-D printing and pharmaceuticals). These therapeutic approaches have encouraging results in the treatment of CAD and related disorders. Research on stem cells focuses on researching the potential for heart regeneration, whereas nanotechnology research studies nano-drug delivery and percutaneous coronary treatments including stent modifications and coatings. The purpose of this article is to give an overview of the research (in vitro, translational, animal, and clinical) pertaining to these innovative approaches and to clarify the reasoning behind their possible use in the treatment of CAD. Through the extensive and continuous efforts of researchers and doctors worldwide, these emerging techniques offer the promise to be viable alternatives to existing therapy modalities. Despite considerable advancements in cardiovascular research, CAD remains one of the most common causes of morbidity and mortality worldwide. However, major inter-collaborative efforts between researchers, physicians and other related professions have led to multi-faceted and unique treatments to be created to treat CAD and its associated problems. Though some of these techniques have good evidence supporting their therapeutic use, some others are still in the experimental stage. Despite only early evidence being available on some of these novel therapy modalities, the results are promising and hold the potential to become alternatives to established treatment options in the future. In the age of evidence-based medicine, more proof in the form of long-term follow-up research and clinical trials is needed before these innovative treatment approaches become commonplace. The future of CAD treatments appears to be very promising with persistent efforts.